Biocon Limited has issued a formal reminder to shareholders holding shares in physical form, emphasizing the urgent need to update their Know Your Customer (KYC) details in accordance with regulatory requirements. The communication, dated April 20, 2026, was sent to both BSE Limited and National Stock Exchange of India Limited as part of the company's compliance obligations under Regulation 30.

Regulatory Compliance Requirements

The reminder stems from SEBI Master Circular no. HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated February 06, 2026, which mandates specific KYC compliance for physical shareholders. According to the circular, security holders whose folios lack updated KYC details will face restrictions on payment eligibility.

Impact on Dividend Payments

Biocon has specifically warned shareholders that dividend payments against their holdings will be withheld if KYC details remain unupdated. The company stated that as mandated by the SEBI Master Circular, any payment including dividend, interest or redemption for non-compliant folios will only be processed through electronic mode upon submission of the required details.

Required Documentation Process

Shareholders must submit specific forms and supporting documents to ensure compliance:

Form ISR-1 Requirements:

• Duly filled form with self-attested supporting documents
• Required for updation of KYC details

Form ISR-2 Requirements:

• Completed form with banker attestation of signature
• Original cancelled cheque with shareholder name(s) printed
• Self-attested copy of bank passbook or statement

Submission Methods and Resources

Shareholders can access the required forms and SEBI Master Circular through multiple channels. The company has provided links to download forms from Biocon's official website under investor relations section and from KFin Technologies Limited's website. The forms and circular are available at the company's shareholder services section and the RTA's client services portal.

Company Communication Details

The reminder letter was signed by Rajesh U. Shanoy, Company Secretary and Compliance Officer (Membership No.: ACS 16328), and digitally signed on April 20, 2026. The communication was sent under reference number BIO/SECL/TG/2026-27/05, demonstrating the company's systematic approach to regulatory compliance and shareholder communication.

Biocon has received a positive outlook from HSBC, which maintains its Buy rating on the biotechnology company with a target price of ₹425. The investment bank's recommendation is based on several strategic improvements and growth catalysts that position the company for enhanced performance.

Strategic Foundation Strengthening

HSBC highlights Biocon's efforts in establishing a strong growth foundation through two critical initiatives. The company has successfully undertaken debt reduction measures alongside corporate simplification strategies, creating a more streamlined operational structure that supports future expansion.

Biosimilar Launch Execution Focus

The investment bank emphasizes management's strategic focus on biosimilar launch execution as a primary driver for the company's growth prospects. HSBC identifies the execution of new biosimilar launches as a key operational priority that is expected to translate into tangible improvements across key financial metrics.

Expected Performance Improvements

HSBC anticipates several positive outcomes from Biocon's strategic initiatives:

• Improving profitability metrics
• Enhanced cash flow generation
• Strengthened operational efficiency
• Better market positioning in biosimilars

Key Growth Catalysts

Market share gains from new biosimilars represent the primary catalyst identified by HSBC for Biocon's future performance. The successful launch and market penetration of these biosimilar products are expected to drive revenue growth and strengthen the company's competitive position in the biotechnology sector.

The combination of debt reduction, corporate simplification, and focused biosimilar execution creates a comprehensive framework for sustainable growth, supporting HSBC's positive outlook and ₹425 target price recommendation.